CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS

Rhea-AI Summary

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) will release its annual financial results for 2022 on March 7, 2023, after market close. A conference call to discuss these results is scheduled for 4:30 p.m. Eastern Time on the same day. Interested parties can register for the call through the provided link. Cumberland focuses on delivering high-quality prescription brands across various therapeutic areas, including hospital acute care and oncology. The company's portfolio includes several FDA-approved products, such as Acetadote® and Vibativ®. Additionally, Cumberland is advancing Phase II clinical programs assessing its ifetroban candidate for several diseases.

Positive

• Scheduled announcement of 2022 financial results and a conference call, providing transparency to shareholders.
• Diverse portfolio of FDA-approved products catering to multiple medical fields.
• Ongoing Phase II clinical programs for ifetroban, indicating potential future growth.

Negative

• None.

NASHVILLE, Tenn., Feb. 28, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022 financial results and provide a company update after the market closes on Tuesday, March 7, 2023.

A conference call will be held March 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIc9d03deed82d47389284c0538fb62962. Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting https://edge.media-server.com/mmc/p/roknyaes.

Cumberland Pharmaceuticals is the largest biopharmaceutical company founded and headquartered in the Mid-South and is focused on the delivery of high-quality, prescription brands designed to improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology, rheumatology, and oncology market segments.

The company's portfolio of FDA-approved brands includes:

• Acetadote^® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
• Caldolor^® (ibuprofen) injection, for the treatment of pain and fever;
• Kristalose^® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
• Omeclamox^®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;
• RediTrex^® (methotrexate) injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis;
• Sancuso^® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
• Vaprisol^® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
• Vibativ^® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy ("DMD"), Systemic Sclerosis ("SSc") and Aspirin-Exacerbated Respiratory Disease ("AERD").

For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website at www.cumberlandpharma.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-annual-2022-financial-results-301758511.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

When will Cumberland Pharmaceuticals announce its annual 2022 financial results?

Cumberland Pharmaceuticals will announce its annual 2022 financial results on March 7, 2023, after market close.

What time is the conference call for Cumberland Pharmaceuticals' financial results?

The conference call for discussing Cumberland Pharmaceuticals' financial results will take place at 4:30 p.m. Eastern Time on March 7, 2023.

How can I participate in the Cumberland Pharmaceuticals conference call?

To participate in the Cumberland Pharmaceuticals conference call, you need to register through the provided link in the press release.

What are some of Cumberland Pharmaceuticals' FDA-approved products?

Cumberland Pharmaceuticals' FDA-approved products include Acetadote®, Caldolor®, and Vibativ® among others.

What is the focus of Cumberland Pharmaceuticals' ongoing clinical programs?

Cumberland Pharmaceuticals' ongoing clinical programs are evaluating the ifetroban product candidate for conditions such as cardiomyopathy associated with Duchenne Muscular Dystrophy.